Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies - Wikidata - awgldk - TriplyDB

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

http://www.wikidata.org/entity/Q33745227

about

Dasatinib as a treatment for Duchenne muscular dystrophy Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy β1-syntrophin modulation by miR-222 in mdx mice.The golden retriever model of Duchenne muscular dystrophy.The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish.The intriguing regulators of muscle mass in sarcopenia and muscular dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.A proteasome inhibitor fails to attenuate dystrophic pathology in mdx mice.Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.Novel intriguing strategies attenuating to sarcopenia Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers.Vascular-targeted therapies for Duchenne muscular dystrophy Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers.The physiological response of protease inhibition in dystrophic muscle.MMP2-9 cleavage of dystroglycan alters the size and molecular composition of Schwann cell domains.Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways.Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy.Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion.Immunoproteasome in animal models of Duchenne muscular dystrophy.Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice.Mouse models of two missense mutations in actin binding domain 1 of dystrophin associated with Duchenne or Becker muscular dystrophy.Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy.At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?

P2860

Q27300846-34198877-B84B-4892-B83F-D7B31DF948B4 Q27332340-4AAD7B12-43D4-43B8-BF3E-D1A7E41490CB Q33697991-D255F059-E230-43F7-A338-AECD9F78707D Q33709114-7D160460-1340-4F06-974C-317ADF34AF81 Q34087155-B79BF3E6-A422-4EAB-8570-1AB47A3D2A24 Q34106342-DBE4F3F6-CF84-403A-9354-20D4693FE56A Q34152280-47857C1F-A4EB-4B16-B2F4-63A3959A7909 Q34154200-0358F9BF-D53E-4ED8-92CD-AB7D63557F72 Q34367192-10ABC1D3-B392-4403-85CE-B71A9BCBFC04 Q34665595-C194DF91-5E59-4D6E-BD06-CEFC82DDAAD2 Q35219135-3FCD03F4-11C7-4081-9299-48323B1171CB Q35829811-DAD44B2C-A07D-4B08-8534-03BE05C19340 Q35836295-156CE904-5932-4FFE-B68D-7C3CAB2A7128 Q36835180-19454D21-2970-448D-8BA5-E1319EDAE06B Q36893329-F22AD4EC-B711-4238-995E-91DBAAD9000B Q37097386-31B22363-B185-4670-805C-F8551B487B69 Q37318251-6C08C65E-7A37-4180-832E-DC04565B9C9A Q38103213-3B93AE60-0DDA-4EFE-A167-1D0DEE1C7E55 Q38104503-9C541DF2-5389-4F24-9A4E-52A129B38E10 Q38349489-AD6F35FC-620B-4F35-979F-5B77C16F1FC5 Q38603674-8EBEA74D-EA9D-4015-92B0-9B05FAEFC294 Q38828129-E1C2DBD4-5888-473D-B5A4-8721E1379483 Q39000126-0AB6F41F-3559-4433-8889-630FE4E4B190 Q39205845-425836AC-9259-4605-843E-FFA5492A3E24 Q42785740-FACFC52B-786A-45E3-B0B4-59289B732125 Q42859444-8B535BF6-1EBF-4203-8B52-CB54D638A88D Q46463712-B6F2D995-F92F-4BDD-8F44-62004DF37BD1 Q47342349-7F105480-97E0-4122-9246-2CAAC210F31C Q50243875-89C5A2E9-72CF-4EF0-8DE8-40E317E426E2 Q51705719-41180B9D-8882-45BF-8AAC-DA4706D60C25 Q55361250-2A4CD586-B919-4A3B-951F-0BCAA8265D4F

P2860

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

http://www.wikidata.org/entity/Q33745227

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@ast

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@en

type

label

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@ast

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@en

prefLabel

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@ast

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@en

P1433

Q33745227-1BE06719-D051-4A67-930F-3A25DCF665AF

P1476

Q33745227-B44C4F07-F803-4F79-AC9D-E8EAF057058C

P2093

Q33745227-060D8710-B0DA-481B-BFC5-1CC1EAE60675

Q33745227-3E8FA1DB-676F-44D1-97A6-F204E7E2A2E1

Q33745227-46A09687-A185-416F-9475-5E3FA9E1B431

Q33745227-50247DD3-936C-4FDA-A692-6BF267D6DC5E

Q33745227-6DF7B6D5-C113-4B98-82A2-F7C863F9C55A

Q33745227-9983140D-0C19-451F-AE54-81C05C50E568

Q33745227-BD548BD8-2058-4FBB-AAB8-0CF4D1129A07

Q33745227-C2AF2651-2275-46C1-8C50-7A4A9B34235B

Q33745227-D39DB59E-9CD7-40E5-9EF2-80A9230293AF

Q33745227-E5F9FD5D-A688-439B-A12E-56A353A4994A

P2860

Q33745227-033AA43A-8A74-4ACE-AD85-4C1B2B74560B

Q33745227-052DF96E-2210-495A-8E2E-95A60F516E7C

Q33745227-13C4E089-158E-480C-9A0E-1442F8C38EC1

Q33745227-148DD354-70DE-44E4-AD3A-52ABBF93A7B2

Q33745227-247A1DE3-4E56-40A8-A4B6-0D975DC797EC

Q33745227-28AAC52D-EF0E-4163-9526-D944DA0CDD09

Q33745227-2DDF984E-9284-400F-939F-FE995369FFF2

Q33745227-3B02626A-33D1-4F3D-959A-372116F2F6B4

Q33745227-3B8472C3-79A2-4630-86F0-7A0329E12B43

Q33745227-3C25D151-5945-4101-ABCE-4235ADA00038

P304

Q33745227-789C0E85-8D80-475D-9AAC-D2A41891830F

P31

Q33745227-B38BF254-3A6F-44AF-9F13-92CBD6493879

P356

Q33745227-D55A6431-54D8-41B2-B2C5-3FDBAB590B7E

P407

Q33745227-3EE7078D-E4B3-4ABE-AA4C-3D51F1619CC5

P433

Q33745227-34FE9F16-ABFB-47FC-9331-AD4B12D466C3

P478

Q33745227-8B4BF9F5-20ED-4D74-BE28-53156B8FDD88

P50

Q33745227-8D1ABD2A-6147-4FBB-BD19-7980769F25F7

Q33745227-DEAB7D0A-822E-48B1-8C41-411B0881228B

P577

Q33745227-F699098B-2739-481E-B782-6F53EA27D9A5

P5875

Q33745227-DE6FE0B1-04E5-4EB4-9CDA-B26BBA7B2352

P698

Q33745227-919274A5-1D1E-49E9-8FB2-23519FA54AFA

P932

Q33745227-929B6397-ED50-417E-9F3F-4E56E1330E57

P356

AJPATH.2010.090468

P1433

The American Journal of Pathology

P1476

Therapeutic potential of prote ...... nd Becker muscular dystrophies

@en

P2093

Andrea Bonetto

http://www.w3.org/2001/XMLSchema#string

Angela Pistorio

http://www.w3.org/2001/XMLSchema#string

Carlo Minetti

http://www.w3.org/2001/XMLSchema#string

Claudio Bruno

http://www.w3.org/2001/XMLSchema#string

Elisabetta Gazzerro

http://www.w3.org/2001/XMLSchema#string

Federico Zara

http://www.w3.org/2001/XMLSchema#string

Gloria Bonuccelli

http://www.w3.org/2001/XMLSchema#string

Michele Cilli

http://www.w3.org/2001/XMLSchema#string

Sonia Scarfì

http://www.w3.org/2001/XMLSchema#string

Stefania Assereto

http://www.w3.org/2001/XMLSchema#string

P2860

Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.

Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB).

Proteasome inhibitors: from research tools to drug candidates.

Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice.

Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.

P304

1863-1877

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.090468

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

Michael P. Lisanti

Federica Sotgia

P577

2010-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42371909

http://www.w3.org/2001/XMLSchema#string

P698

20304949

http://www.w3.org/2001/XMLSchema#string

P932

2843476

http://www.w3.org/2001/XMLSchema#string